DFTX (Definium Therapeutics) Total Stockholders Equity: $278.85 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DFTX Definium Therapeutics Inc DFTX
32 GF Score
Price $42.80
! 5 Warning Signs
View Full Analysis

What is Definium Therapeutics Total Stockholders Equity?

Definium Therapeutics DFTX -3.36% 32 Total Stockholders Equity is $278.85 Mil as of Mar. 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

Definium Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $278.85 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Definium Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $2.68. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Definium Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.15.

Definium Therapeutics  (NAS:DFTX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Definium Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(278.849-0)/104.045
=2.68

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Definium Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 40.773) / 278.849
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Definium Therapeutics Total Stockholders Equity Related Terms

Definium Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Definium Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Definium Therapeutics Total Stockholders Equity Chart

Definium Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 151.66 150.92 78.13 241.45 332.33

Definium Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 222.81 185.40 130.60 332.33 278.85
DFTX
32GF Score
Definium Therapeutics Inc DFTX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $278.85 Mil mean?
Definium Therapeutics (DFTX) has a Total Stockholders Equity of $278.85 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Definium Therapeutics and its competitors.
Is Definium Therapeutics' Total Stockholders Equity too high?
Definium Therapeutics' current Total Stockholders Equity is $278.85 Mil. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' Total Stockholders Equity compare to LGND and XENE?
Definium Therapeutics' Total Stockholders Equity of $278.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Definium Therapeutics and its competitors. Definium Therapeutics's current Total Stockholders Equity is $278.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current Total Stockholders Equity of $278.85 Mil. The current Total Stockholders Equity is $278.85 Mil. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current Total Stockholders Equity is $278.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Other Exchanges MMQ0:Germany
Address One World Trade Center, Suite 8500, New York, NY, USA, 10007
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
32GF Score

Get the complete analysis for DFTX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.80
Price